益安生醫

SEQ_NO	1	Date of announcement	2025/10/03	Time of announcement	16:10:56
Subject	Announcement on Matters Relating to the Record Date for the Company’s 2025 Cash Capital Increase
Date of events	2024/10/03	To which item it meets	paragraph 11
Statement	1.Date of the board of directors resolution or decision by the Company for record date:2024/10/03 2.Whether to adopt shelf registration (Yes, please state issuance period /No): No 3.Effective registration date approved by competent authority:2025/10/02 4.Date of the board of directors resolution for (additional) issuance of shares:2024/09/01 5.Total monetary value of the issuance and number of shares issued: Issuance Amount: NT$47,000,000 Number of Shares Issued: 4,700,000 common shares 6.If adopting shelf registration, monetary value and number of shares to be issued this time:NA 7.The remaining monetary value and shares after this issuance when adopting shelf registration:NA 8.Par Value per share:NT$10 9.Issue price: The actual issuance price shall be determined by the Chairman, upon approval of the competent authority, in consultation with the lead underwriter and in accordance with Article 6 of the ‘Self-Regulation Rules for Securities Underwriters Assisting Companies in Offering and Issuing Securities’ of the ROC Securities Association and other applicable laws and regulations. 10.Number of shares subscribed for by employees: In accordance with Article 267 of the Company Act, 15% of the total shares to be issued, amounting to 705,000 shares, shall be reserved for subscription by the Company’s employees. 11.Ratio of shares subscribed for by existing shareholders: 75% of the newly issued shares shall be subscribed by shareholders listed in the shareholders’ register on the subscription record date, in proportion to their respective shareholdings. 12.Method for public sale and no.of shares: In accordance with Article 28-1 of the Securities and Exchange Act, 10% of the total issued shares shall be allocated for public offering. 13.Handling method for fractional shares and shares unsubscripted for by the deadline: Fractional shares resulting from subscriptions of less than one full share may be combined into whole shares by shareholders directly with the Company’s stock transfer agent within five days from the suspension of share transfer. Shares that are forfeited by existing shareholders or employees who waive their subscription rights, or any remaining fractional shares, are hereby authorized to be subscribed by the Chairman, on behalf of the Company, by designated persons at the issuance price. 14.Rights and obligations of these newly issued shares: The new shares issued in this cash capital increase will be issued in dematerialized form and shall carry the same rights and obligations as the existing shares. 15.Utilization of the funds from the current capital increase: Investee subsidiary 16.Record date of cash capital increase and share subscription: 2025/10/30 17.Last date before book closure:2025/10/25 18.Book closure starting date:2025/10/26 19.Book closure ending date:2025/10/30 20.Payment period: (1) Existing shareholders or employees: 2025/11/05~2025/12/05 (2) Designated persons: 2025/12/08-2025/12/16 21.Date of the agreement with the banks to collect and deposit the proceeds: An announcement will be made separately upon execution of the agreement. 22.Name of the institution designated to collect the proceeds: An announcement will be made separately upon execution of the agreement. 23.Name of the bank designated to deposit the proceeds: An announcement will be made separately upon execution of the agreement. 24.Any other matters that need to be specified: The key details of this cash capital increase plan include the source of funds, planned projects, expected schedule, and anticipated benefits. Should there be any amendments required by the competent authority, any matters not fully addressed, or changes necessitated by objective circumstances, the Company intends to request the Board of Directors to authorize the Chairman to handle such matters with full discretion. If the actual issuance price per share is adjusted due to market fluctuations and results in a shortfall in the funds to be raised, the shortfall shall be covered by the Company’s own funds. Conversely, if the funds raised exceed the target, the surplus shall be used to strengthen the Company’s operating capital.